Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma
Ines Pires Da Silva, Tasnia Ahmed, Jennifer L. McQuade, Caroline A. Nebhan, John J. Park, Judith M. Versluis, Patricio Serra-Bellver, Yasir Khan, Tim Slattery, Honey K. Oberoi, Selma Ugurel, Lauren E. Haydu, Rudolf Herbst, Jochen Utikal, Claudia Pfohler, Patrick Terheyden, Michael Weichenthal, Ralf Gutzmer, Peter Mohr, Rajat RaiJessica L. Smith, Richard A. Scolyer, Ana M. Arance, Lisa Pickering, James Larkin, Paul Lorigan, Christian U. Blank, Dirk Schadendorf, Michael A. Davies, Matteo S. Carlino, Douglas B. Johnson, Georgina V. Long, Serigne N. Lo, Alexander M. Menzies*
Untersuchen Sie die Forschungsthemen von „Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma“. Zusammen bilden sie einen einzigartigen Fingerprint.